Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06387225

Early and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients

Cerebral lesions are responsible for two thirds of deaths in patients admitted to intensive care following cardiac arrest. Patients with neurological lesions should be the priority target for neuroprotective interventions, which are the cornerstone of post-cardiac arrest care (allowing a reduction in the burden of care for patients without this type of lesion). Furthermore, these interventions must be based on a precise assessment of the severity of these brain lesions: carrying out neuro-protective interventions in patients without brain lesions exposes these patients to unnecessary treatment potentially associated with adverse effects without any possible benefit. However, the early assessment of neurological prognosis, particularly on admission to intensive care, is an area where there is little research and where it is not possible to obtain a precise and reproducible assessment. Several tools can be used to assess this prognosis at an early stage: anamnesis and characteristics of the cardiac arrest and the patient's comorbidities, imaging, electrophysiology and biomarkers.

To assess the predictive value of early biomarker testing in patients resuscitated after cardiac arrest, whatever the cause, the investigators plan to conduct a prospective observational multicentre trial.

It is important to bear in mind that the aim of this study is not to assess the long-term prognosis of patients suffering cardiac arrest in order to take measures to limit or discontinue active therapies, but simply to provide a reliable tool, simple and quick to use, in order to be able to identify a sub-population of patients who should be the subject of preferential neuro-protection measures, and conversely to simplify management (moderate temperature control, early cessation of sedation, early extubation) for patients with no neurological lesions.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHD Vendée, La Roche-sur-Yon, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Admitted to intensive care with out-of-hospital cardiac arrest
  • Comatose on admission (defined by a Glasgow score ≤ 8)
  • Informed relative who has consented to the patient's participation in the study or inclusion under emergency procedure if the relative is absent at the time of inclusion

Exclusion criteria

  • In-hospital cardiac arrest
  • Age < 18 years
  • Person under guardianship or legal protection
  • Prior inclusion in the study

Treatment and study plan

Primary outcomes

  1. Dosage of biomarker UCHL-1 (Ubiquitin carboxy-terminal hydrolase L1) at the time of admission to intensive care

    Time frame: at ICU admission

    Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90

  2. Dosage of biomarker GFAP (Glial fibrillary acidic protein) at the time of admission to intensive care

    Time frame: at ICU admission

    Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90

  3. Neurological outcome at D90 assessed by modified Rankin scale (mRS)

    Time frame: 90 days after patient enrolment in the study

    Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90

Secondary outcomes

  1. Dosage of biomarkers UCHL-1 ((Ubiquitin carboxy-terminal hydrolase L1) at the time of admission to intensive care

    Time frame: at ICU admission

    Determine prognostic value (positive and negative predictive value (PPV/NPV), positive and negative likelihood ratio (LR+/LR-) of each biomarker separately according to the threshold on admission.

    Determine the value of combining the two biomarkers at admission.

  2. Dosage of biomarkers GFAP (Glial fibrillary acidic protein) at the time of admission to intensive care

    Time frame: at ICU admission

    Determine prognostic value (positive and negative predictive value (PPV/NPV), positive and negative likelihood ratio (LR+/LR-) of each biomarker separately according to the threshold on admission.

    Determine the value of combining the two biomarkers at admission.

  3. Dosage of biomarkers UCHL-1 (Ubiquitin carboxy-terminal hydrolase L1) at 4 hours for recovery of effective cardiac activity (RACS)

    Time frame: at 4 hours for recovery of effective cardiac activity (RACS)

    Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90.

    Determine interest of combining the two biomarkers at H4 of the RACS.

  4. Dosage of biomarkers GFAP( Glial fibrillary acidic protein) at 4 hours for recovery of effective cardiac activity (RACS)

    Time frame: at 4 hours for recovery of effective cardiac activity (RACS)

    Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90.

    Determine interest of combining the two biomarkers at H4 of the RACS.

  5. Neurological outcome at D90 assessed by modified Rankin scale (mRS) ranging from 0 to 6

    Time frame: 90 days after patient enrolment in the study

    Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90.

    A score of 0 to 3 is considered a favorable neurological outcome.

Study contacts

Contact information is provided by the study sponsor or research team.

Jean-Baptiste LASCARROU

CONTACT

[email protected]

0240087386

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Acronym: HYPERION-2

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 26, 2024
Registry last updated
Feb 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.